Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

Research output: Contribution to journalArticle

Standard

Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. / Kreutzman, A.; Ladell, K.; Koechel, C.; Gostick, E.; Ekblom, Marja; Stenke, L.; Melo, T.; Einsele, H.; Porkka, K.; Price, D. A.; Mustjoki, S.; Seggewiss, R.

In: Leukemia, Vol. 25, No. 10, 2011, p. 1587-1597.

Research output: Contribution to journalArticle

Harvard

Kreutzman, A, Ladell, K, Koechel, C, Gostick, E, Ekblom, M, Stenke, L, Melo, T, Einsele, H, Porkka, K, Price, DA, Mustjoki, S & Seggewiss, R 2011, 'Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation', Leukemia, vol. 25, no. 10, pp. 1587-1597. https://doi.org/10.1038/leu.2011.135

APA

CBE

Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA, Mustjoki S, Seggewiss R. 2011. Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 25(10):1587-1597. https://doi.org/10.1038/leu.2011.135

MLA

Vancouver

Author

Kreutzman, A. ; Ladell, K. ; Koechel, C. ; Gostick, E. ; Ekblom, Marja ; Stenke, L. ; Melo, T. ; Einsele, H. ; Porkka, K. ; Price, D. A. ; Mustjoki, S. ; Seggewiss, R. / Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. In: Leukemia. 2011 ; Vol. 25, No. 10. pp. 1587-1597.

RIS

TY - JOUR

T1 - Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

AU - Kreutzman, A.

AU - Ladell, K.

AU - Koechel, C.

AU - Gostick, E.

AU - Ekblom, Marja

AU - Stenke, L.

AU - Melo, T.

AU - Einsele, H.

AU - Porkka, K.

AU - Price, D. A.

AU - Mustjoki, S.

AU - Seggewiss, R.

PY - 2011

Y1 - 2011

N2 - The tyrosine kinase inhibitor dasatinib exerts immunosuppressive effects on T-cells and NK-cells in vitro. However, in some dasatinib-treated leukemia patients, clonal lymphocytosis with large granular lymphocyte (LGL) morphology develops, and this is associated with enhanced therapeutic responses. To elucidate the mechanistic basis for this paradoxical observation, we conducted detailed phenotypic and functional analyses of T-cell and NK-cell populations from 25 dasatinib-treated leukemia patients. All tested patients with LGL expansions (15/16) were cytomegalovirus (CMV) immunoglobulin (IgG) seropositive with high frequencies of CMV-specific CD8(+) T-cells; 5/16 LGL patients also experienced symptomatic CMV reactivation during dasatinib therapy. Expanded T-cell and NK-cell populations exhibited late differentiated (CD27(_)(-) CD57(+)) phenotypes; this was associated with a predisposition to apoptosis within the T-cell compartment and impaired NK-cell cytotoxicity. Only 3/9 non-LGL patients were CMV IgG seropositive. Dasatinib inhibited in vitro lymphocyte functions, similarly in LGL patients and controls. Notably, distinct CD8(high) and CD8(low) T-cell subsets were observed in LGL patients; this phenotypic dichotomy was also apparent in CMV-specific CD8(+) T-cell populations, and exhibited features consistent with antigen-driven activation. In addition, plasma levels of IP-10, IL-6, monokine induced by interferon-c and interleukin-2R were significantly increased in LGL patients. These data provide evidence that dasatinib-associated LGL expansion is linked to CMV reactivation and suggest a potential mechanism for this phenomenon. Leukemia (2011) 25, 1587-1597; doi:10.1038/leu.2011.135; published online 7 June 2011

AB - The tyrosine kinase inhibitor dasatinib exerts immunosuppressive effects on T-cells and NK-cells in vitro. However, in some dasatinib-treated leukemia patients, clonal lymphocytosis with large granular lymphocyte (LGL) morphology develops, and this is associated with enhanced therapeutic responses. To elucidate the mechanistic basis for this paradoxical observation, we conducted detailed phenotypic and functional analyses of T-cell and NK-cell populations from 25 dasatinib-treated leukemia patients. All tested patients with LGL expansions (15/16) were cytomegalovirus (CMV) immunoglobulin (IgG) seropositive with high frequencies of CMV-specific CD8(+) T-cells; 5/16 LGL patients also experienced symptomatic CMV reactivation during dasatinib therapy. Expanded T-cell and NK-cell populations exhibited late differentiated (CD27(_)(-) CD57(+)) phenotypes; this was associated with a predisposition to apoptosis within the T-cell compartment and impaired NK-cell cytotoxicity. Only 3/9 non-LGL patients were CMV IgG seropositive. Dasatinib inhibited in vitro lymphocyte functions, similarly in LGL patients and controls. Notably, distinct CD8(high) and CD8(low) T-cell subsets were observed in LGL patients; this phenotypic dichotomy was also apparent in CMV-specific CD8(+) T-cell populations, and exhibited features consistent with antigen-driven activation. In addition, plasma levels of IP-10, IL-6, monokine induced by interferon-c and interleukin-2R were significantly increased in LGL patients. These data provide evidence that dasatinib-associated LGL expansion is linked to CMV reactivation and suggest a potential mechanism for this phenomenon. Leukemia (2011) 25, 1587-1597; doi:10.1038/leu.2011.135; published online 7 June 2011

KW - CMV

KW - dasatinib

KW - LGL

KW - NK-cells

KW - T-cells

U2 - 10.1038/leu.2011.135

DO - 10.1038/leu.2011.135

M3 - Article

VL - 25

SP - 1587

EP - 1597

JO - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

T2 - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

JF - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

SN - 1476-5551

IS - 10

ER -